{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T14:49:13Z","timestamp":1784731753319,"version":"3.55.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.urolonc.2012.05.002","type":"journal-article","created":{"date-parts":[[2012,7,3]],"date-time":"2012-07-03T16:32:53Z","timestamp":1341333173000},"page":"1522-1526","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and\/or suspicious digital rectal examination. First Latin American experience"],"prefix":"10.1016","volume":"31","author":[{"given":"Christian G.","family":"Ramos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Valdevenito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivonne","family":"Vergara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricio","family":"Anabalon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Fulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2012.05.002_bib1","first-page":"1975","article-title":"SEER cancer statistics review","author":"Altekruse","year":"2010"},{"key":"10.1016\/j.urolonc.2012.05.002_bib2","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","article-title":"Screening and prostate-cancer mortality in a randomized European study","volume":"360","author":"Schr\u00f6der","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2012.05.002_bib3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nrclinonc.2012.52","article-title":"Screening: PSA screening reduced mortality from prostate cancer","volume":"9","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.urolonc.2012.05.002_bib4","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.acuro.2010.02.019","article-title":"Assessment of the PCA3 test for prostate cancer diagnosis: A systematic review and meta-analysis","volume":"34","author":"Ruiz-Arag\u00f3n","year":"2010","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.urolonc.2012.05.002_bib5","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1002\/pros.21011","article-title":"Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: A randomized, open-label, parallel-group pilot study","volume":"69","author":"van Gils","year":"2009","journal-title":"Prostate"},{"key":"10.1016\/j.urolonc.2012.05.002_bib6","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/sj.bjc.6605648","article-title":"Impact of prostate cancer testing: An evaluation of the emotional consequences of a negative biopsy result","volume":"102","author":"Macefield","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2012.05.002_bib7","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1016\/j.juro.2009.08.056","article-title":"Validation in a multiple urology practice cohort of the prostate cancer prevention trial calculator for predicting prostate cancer detection","volume":"182","author":"Eyre","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2012.05.002_bib8","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/MOU.0b013e328344939c","article-title":"Contemporary role of prostate cancer gene 3 in the management of prostate cancer","volume":"21","author":"Roobol","year":"2011","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.urolonc.2012.05.002_bib9","first-page":"5975","article-title":"DD3: A new prostate-specific gene, highly overexpressed in prostate cancer","volume":"59","author":"Bussemakers","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2012.05.002_bib10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0302-2838(03)00201-X","article-title":"DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer","volume":"44","author":"Hessels","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2012.05.002_bib11","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrurol.2009.40","article-title":"The use of PCA3 in the diagnosis of prostate cancer","volume":"6","author":"Hessels","year":"2009","journal-title":"Nat. Rev Urol"},{"key":"10.1016\/j.urolonc.2012.05.002_bib12","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.eururo.2010.06.039","article-title":"Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: Exploring the value of PCA3 for a first-line diagnostic test","volume":"58","author":"Roobol","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2012.05.002_bib13","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.eururo.2010.10.024","article-title":"Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging","volume":"59","author":"Auprich","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2012.05.002_bib14","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.eururo.2008.06.071","article-title":"Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy","volume":"54","author":"Haese","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2012.05.002_bib15","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.juro.2007.11.038","article-title":"PCA3: A molecular urine assay for predicting prostate biopsy outcome","volume":"179","author":"Deras","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2012.05.002_bib16","first-page":"70","article-title":"American Cancer Society guideline for the early detection of prostate cancer: Update 2010","volume":"60","author":"Wolf","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2012.05.002_bib17","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1373\/clinchem.2005.063289","article-title":"APTIMA PCA3 molecular urine test: Development of a method to aid in the diagnosis of prostate cancer","volume":"52","author":"Groskopf","year":"2006","journal-title":"Clin Chem"},{"key":"10.1016\/j.urolonc.2012.05.002_bib18","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.urology.2006.12.014","article-title":"PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy","volume":"69","author":"Marks","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2012.05.002_bib19","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.urology.2009.03.046","article-title":"Urinary prostate cancer 3 test: Toward the age of reason?","volume":"75","author":"Vlaeminck-Guillem","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2012.05.002_bib20","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/j.juro.2010.06.098","article-title":"PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: Validation in the placebo arm of the dutasteride REDUCE trial","volume":"184","author":"Aubin","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2012.05.002_bib21","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1158\/1078-0432.CCR-06-2679","article-title":"The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance","volume":"13","author":"van Gils","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2012.05.002_bib22","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1158\/0008-5472.CAN-07-3224","article-title":"A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer","volume":"68","author":"Laxman","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2012.05.002_bib23","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.eururo.2010.09.030","article-title":"Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in prescreened men: Reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (\u2265100)","volume":"58","author":"Roobol","year":"2010","journal-title":"Eur Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143912001640?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143912001640?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:00:07Z","timestamp":1761040807000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143912001640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S1078143912001640"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2012.05.002","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and\/or suspicious digital rectal examination. First Latin American experience","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2012.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}